Sudhindran Surendran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sudhindran Surendran has a total of 731 co-authors. Here are the top co-authors by number of shared publications:
Dinesh Balakrishnan
Department of Gastrointestinal Surgery and Solid Organ Transplantation, Amrita Institute of Medical Sciences and Research Centre, Amrita University, Kochi, Kerala, India
25 shared publications- Puneet Dhar
Surgical Gastroenterology, All India Institute of Medical Sciences, Rishikesh, IND
17 shared publications Unnikrishnan Gopalakrishnan
Department of Gastrointestinal Surgery and Solid Organ Transplantation, Amrita Institute of Medical Sciences and Research Centre, Amrita University, Kochi, Kerala, India
14 shared publicationsShweta Mallick
Department of Gastrointestinal Surgery and Solid Organ Transplantation, Amrita Institute of Medical Sciences and Research Centre, Amrita University, Kochi, Kerala, India
13 shared publicationsRamachandran Narayana Menon
GI Surgery, Amrita Institute of Medical Sciences & Research Centre, Kochi Coimbatore Tamil Nadu Amrita Vishwa Vidyapeetham
10 shared publicationsKrishnanunni Nair
GI Surgery, Amrita Institute of Medical Sciences & Research Centre, Kochi Coimbatore Tamil Nadu Amrita Vishwa Vidyapeetham
9 shared publications
Latest Publications
- 26 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 31 (6) , 368-373
Challenges in obese liver transplant recipients
Purpose of review: The global obesity epidemic has significantly altered the epidemiology of chronic liver disease and liver transplantation, with metabolic dysfunction-associated steatohepatitis emerging as a rapidly increasing indication for liver transplantation worldwide. Obesity in liver transplantation candidates is frequently accompanied by sarcopenia, frailty, cardiovascular disease, and metabolic comorbidities, creating complex perioperative and long-term management challenges. This review summarizes contemporary evidence regarding assessment, pretransplant preparation, perioperative management, and long-term outcomes of obese liver transplant recipients, while highlighting evolving therapeutic strategies and unresolved clinical questions. Recent findings: Recent literature emphasizes that BMI alone inadequately characterizes obesity in cirrhosis, with body composition, sarcopenic obesity, visceral adiposity, and frailty emerging as important prognostic factors. Structured prehabilitation, lifestyle modification, incretin-based pharmacotherapy, and selective metabolic bariatric surgery have shown promising results in carefully selected patients. Although obesity increases perioperative complexity and postoperative complications, carefully selected obese recipients can achieve graft and patient survival comparable to nonobese recipients. Summary: Obesity should not be considered a contraindication to liver transplantation. Individualized recipient assessment, coordinated perioperative optimization, and long-term metabolic surveillance are essential to improve outcomes. Future research should refine obesity assessment beyond BMI and clarify the optimal integration of pharmacologic and surgical weight-loss strategies in liver transplantation candidates before and after transplantation.
- 26 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 31 (6) , 368-373
Challenges in obese liver transplant recipients
Purpose of review: The global obesity epidemic has significantly altered the epidemiology of chronic liver disease and liver transplantation, with metabolic dysfunction-associated steatohepatitis emerging as a rapidly increasing indication for liver transplantation worldwide. Obesity in liver transplantation candidates is frequently accompanied by sarcopenia, frailty, cardiovascular disease, and metabolic comorbidities, creating complex perioperative and long-term management challenges. This review summarizes contemporary evidence regarding assessment, pretransplant preparation, perioperative management, and long-term outcomes of obese liver transplant recipients, while highlighting evolving therapeutic strategies and unresolved clinical questions. Recent findings: Recent literature emphasizes that BMI alone inadequately characterizes obesity in cirrhosis, with body composition, sarcopenic obesity, visceral adiposity, and frailty emerging as important prognostic factors. Structured prehabilitation, lifestyle modification, incretin-based pharmacotherapy, and selective metabolic bariatric surgery have shown promising results in carefully selected patients. Although obesity increases perioperative complexity and postoperative complications, carefully selected obese recipients can achieve graft and patient survival comparable to nonobese recipients. Summary: Obesity should not be considered a contraindication to liver transplantation. Individualized recipient assessment, coordinated perioperative optimization, and long-term metabolic surveillance are essential to improve outcomes. Future research should refine obesity assessment beyond BMI and clarify the optimal integration of pharmacologic and surgical weight-loss strategies in liver transplantation candidates before and after transplantation.
- Open Access
- 1 October 2026
- Published by Elsevier in Journal of Hepatology
Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study
- 1 October 2026
- Published by Elsevier in Journal of Hepatology
Open AccessSurvival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study
- 27 June 2026
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 16 (5) , 103598
Clinicopathological profile and outcomes of severe hepatitis A outbreak in India: A multicenter cross-sectional study
- 27 June 2026
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 16 (5) , 103598
Clinicopathological profile and outcomes of severe hepatitis A outbreak in India: A multicenter cross-sectional study
- 17 June 2026
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 16 (5) , 103588
Impact of Pre-operative Single-dose Methylprednisolone on Outcomes After Major Hepatectomy in Adults: A Prospective, Randomised Controlled Trial
- 17 June 2026
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 16 (5) , 103588
Impact of Pre-operative Single-dose Methylprednisolone on Outcomes After Major Hepatectomy in Adults: A Prospective, Randomised Controlled Trial
- Open Access
- 11 March 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 9
FXR agonist in post-liver transplantation patients: a randomized open-labeled study. [Protocol]
Liver diseases cause nearly 2 million deaths worldwide each year, with approximately 1 million deaths from cirrhosis complications and another 1 million from viral hepatitis and liver cancer, according to WHO estimates. Liver transplantation (LT) remains the primary curative option, boasting success rates of 85% in the first year and 75% at five years post-transplant. Despite high costs, LT is considered cost-effective, especially for younger patients with active work years remaining. However, post-transplant complications, particularly intrahepatic cholestasis, present notable challenges. This complication arises from factors such as ischemia-reperfusion injury, infections, immunological rejection, and surgical complications, all contributing to impaired bile flow and liver damage. Current medical therapies for post-LT cholestasis are limited, with ursodeoxycholic acid (UDCA) frequently used, despite questionable efficacy. Obeticholic acid (OCA), a potent Farnesoid X Receptor (FXR) agonist approved by the FDA for treating primary biliary cholangitis (PBC), has shown potential benefits in reducing elevated cholestatic liver enzymes. Given its significant effects on liver health, OCA may offer therapeutic value in managing post-transplant cholestasis and improving graft survival. This randomized controlled trial (RCT) aims to evaluate OCA’s efficacy compared to UDCA in reducing cholestatic injury and enhancing graft function post-LT. The primary outcomes will focus on a 15% reduction in alkaline phosphatase and gamma-glutamyl transferase levels at 3, 6, and 12 months from baseline one month. Secondary outcomes include molecular markers, biliary complications, graft rejection, quality of life, and cost-effectiveness. Results are anticipated to demonstrate that OCA could ameliorate cholestasis, improve graft survival, reduce post-transplant complications, and enhance quality of life, potentially setting a new standard in post-LT care if found beneficial.
- 11 March 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 9
Open AccessFXR agonist in post-liver transplantation patients: a randomized open-labeled study. [Protocol]
Liver diseases cause nearly 2 million deaths worldwide each year, with approximately 1 million deaths from cirrhosis complications and another 1 million from viral hepatitis and liver cancer, according to WHO estimates. Liver transplantation (LT) remains the primary curative option, boasting success rates of 85% in the first year and 75% at five years post-transplant. Despite high costs, LT is considered cost-effective, especially for younger patients with active work years remaining. However, post-transplant complications, particularly intrahepatic cholestasis, present notable challenges. This complication arises from factors such as ischemia-reperfusion injury, infections, immunological rejection, and surgical complications, all contributing to impaired bile flow and liver damage. Current medical therapies for post-LT cholestasis are limited, with ursodeoxycholic acid (UDCA) frequently used, despite questionable efficacy. Obeticholic acid (OCA), a potent Farnesoid X Receptor (FXR) agonist approved by the FDA for treating primary biliary cholangitis (PBC), has shown potential benefits in reducing elevated cholestatic liver enzymes. Given its significant effects on liver health, OCA may offer therapeutic value in managing post-transplant cholestasis and improving graft survival. This randomized controlled trial (RCT) aims to evaluate OCA’s efficacy compared to UDCA in reducing cholestatic injury and enhancing graft function post-LT. The primary outcomes will focus on a 15% reduction in alkaline phosphatase and gamma-glutamyl transferase levels at 3, 6, and 12 months from baseline one month. Secondary outcomes include molecular markers, biliary complications, graft rejection, quality of life, and cost-effectiveness. Results are anticipated to demonstrate that OCA could ameliorate cholestasis, improve graft survival, reduce post-transplant complications, and enhance quality of life, potentially setting a new standard in post-LT care if found beneficial.
- 20 January 2026
- Published by Springer Nature
- p. 571-586
Immediate Postoperative Care
- Open Access
- 30 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12)
Predictive Value of Procalcitonin and C-reactive Protein for Mortality in Live Donor Liver Transplant Recipients
Background: Accurate biomarkers are crucial for the early diagnosis of sepsis after liver transplantation. This study aimed to evaluate the diagnostic accuracy of procalcitonin (PCT) and C-reactive protein (CRP) in predicting bacterial infections and mortality following living donor liver transplantation (LDLT). Methodology: We prospectively analyzed all adult LDLT patients at a tertiary center between January 2021 and December 2022. CRP and PCT levels were measured on postoperative days (POD) one, three, five, and seven, and compared among patients without infections, those with bloodstream infections, and those with other infections (urinary, bronchoalveolar lavage, or drain). Multivariate logistic regression assessed the impact of PCT and CRP trends on short- and long-term mortality. Results: Among 216 LDLT patients, 122 (56%) were analyzed after applying exclusion criteria. In patients without infections, median CRP and PCT levels were elevated on days one (CRP: 19, interquartile range (IQR): 11-29; PCT: 3, IQR: 1-13) and three (CRP: 18, IQR: 7-30; PCT: 2, IQR: 1-9) but decreased by days five (CRP: 10, IQR: 5-16; PCT: 1, IQR: 0.2-3) and seven (CRP: 10, IQR: 3-17; PCT: 0.7, IQR: 0.3-3). No absolute values of CRP or PCT effectively diagnosed infections. Patients with a decreasing trend in CRP from POD three to five to seven had survival rates of 90%, 86%, and 85% at 30, 90, and 600 days, respectively; in contrast, those with an increasing CRP trend had lower survival rates of 78%, 71%, and 40%, respectively. Similarly, a decline in PCT was associated with 30-, 90-, and 600-day survival rates of 90%, 85%, and 84%, while increasing PCT correlated with significantly lower rates of 75%, 70%, and 30%, respectively. Conclusion: While the absolute values of CRP and PCT were not diagnostic for infection, an increase in these biomarkers from days three to five to seven predicted significantly higher short- and long-term mortality in LDLT recipients.
- 30 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12)
Open AccessPredictive Value of Procalcitonin and C-reactive Protein for Mortality in Live Donor Liver Transplant Recipients
Background: Accurate biomarkers are crucial for the early diagnosis of sepsis after liver transplantation. This study aimed to evaluate the diagnostic accuracy of procalcitonin (PCT) and C-reactive protein (CRP) in predicting bacterial infections and mortality following living donor liver transplantation (LDLT). Methodology: We prospectively analyzed all adult LDLT patients at a tertiary center between January 2021 and December 2022. CRP and PCT levels were measured on postoperative days (POD) one, three, five, and seven, and compared among patients without infections, those with bloodstream infections, and those with other infections (urinary, bronchoalveolar lavage, or drain). Multivariate logistic regression assessed the impact of PCT and CRP trends on short- and long-term mortality. Results: Among 216 LDLT patients, 122 (56%) were analyzed after applying exclusion criteria. In patients without infections, median CRP and PCT levels were elevated on days one (CRP: 19, interquartile range (IQR): 11-29; PCT: 3, IQR: 1-13) and three (CRP: 18, IQR: 7-30; PCT: 2, IQR: 1-9) but decreased by days five (CRP: 10, IQR: 5-16; PCT: 1, IQR: 0.2-3) and seven (CRP: 10, IQR: 3-17; PCT: 0.7, IQR: 0.3-3). No absolute values of CRP or PCT effectively diagnosed infections. Patients with a decreasing trend in CRP from POD three to five to seven had survival rates of 90%, 86%, and 85% at 30, 90, and 600 days, respectively; in contrast, those with an increasing CRP trend had lower survival rates of 78%, 71%, and 40%, respectively. Similarly, a decline in PCT was associated with 30-, 90-, and 600-day survival rates of 90%, 85%, and 84%, while increasing PCT correlated with significantly lower rates of 75%, 70%, and 30%, respectively. Conclusion: While the absolute values of CRP and PCT were not diagnostic for infection, an increase in these biomarkers from days three to five to seven predicted significantly higher short- and long-term mortality in LDLT recipients.
- 10 December 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (5) , E13-E14
Reply: Tackling the learning curve for safe robotic living donor hepatectomy
- 10 December 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (5) , E13-E14
Reply: Tackling the learning curve for safe robotic living donor hepatectomy
- Open Access
- 27 November 2025
- Published by Springer Nature in Cureus
- Vol. 17 (11) , e97915
Role of FXR Agonist in Cholestasis Following Live Donor Liver Transplantation: A Randomized Open-Label Trial
Background: Intrahepatic cholestasis is a frequent postoperative issue in living donor liver transplantation (LDLT), typically stemming from causes such as reperfusion-related damage, infections, biliovascular issues, or rejection. Prompt intervention is key to preserving graft viability and promoting long-term recovery. Objective: To evaluate the safety and efficacy of obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, versus ursodeoxycholic acid (UDCA) in post-liver transplant patients to ameliorate cholestatic injury and reduce biopsy-proven rejection. Methodology: In this randomized, open-label trial, adult LDLT recipients received OCA (5 mg/day) or UDCA (300 mg thrice daily) from postoperative day 3 for one year. The primary endpoint was ≥15% reduction in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) from one-month postoperative baseline assessed at three, six, and 12 months. Secondary outcomes included changes in relevant biochemical tests and molecular parameters like plasma bile acids, transforming growth factor-beta (TGF-β), cytokeratin-18 (CK-18), serum autotaxin, fibroblast growth factor-19 (FGF-19), and bile salt export pump (BSEP), as well as the incidence of rejection, early allograft dysfunction (EAD), biliary complications, mortality, adverse events, and quality of life (QoL). Results: In the interim analysis of 83 patients, more than a 15% reduction in ALP between six and 12 months was observed in a higher proportion of patients in the OCA group (43%) than in the UDCA group (21%) (p=0.036). More than a 15% reduction in GGT between one and three months was observed in 80% of patients in the OCA group compared to 62% in the UDCA group (p=0.062). Plasma bile acids were lower in the OCA group at one month (170 vs. 226 µmol/L; p=0.012). Low-density lipoprotein (LDL)-cholesterol was higher in the OCA group at three (OCA 121 vs UDCA 107, p=0.027) and six months (OCA 130 vs UDCA 117, p=0.043). UDCA therapy resulted in a significantly greater improvement in overall QoL, with higher gains in both total mean and domain scores compared to OCA. No differences were detected in rejection, biliary complications, mortality, or other secondary endpoints. Conclusion: OCA led to greater biochemical improvement, while better QoL was achieved with UDCA in LDLT recipients, with a comparable safety profile.
- 27 November 2025
- Published by Springer Nature in Cureus
- Vol. 17 (11) , e97915
Open AccessRole of FXR Agonist in Cholestasis Following Live Donor Liver Transplantation: A Randomized Open-Label Trial
Background: Intrahepatic cholestasis is a frequent postoperative issue in living donor liver transplantation (LDLT), typically stemming from causes such as reperfusion-related damage, infections, biliovascular issues, or rejection. Prompt intervention is key to preserving graft viability and promoting long-term recovery. Objective: To evaluate the safety and efficacy of obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, versus ursodeoxycholic acid (UDCA) in post-liver transplant patients to ameliorate cholestatic injury and reduce biopsy-proven rejection. Methodology: In this randomized, open-label trial, adult LDLT recipients received OCA (5 mg/day) or UDCA (300 mg thrice daily) from postoperative day 3 for one year. The primary endpoint was ≥15% reduction in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) from one-month postoperative baseline assessed at three, six, and 12 months. Secondary outcomes included changes in relevant biochemical tests and molecular parameters like plasma bile acids, transforming growth factor-beta (TGF-β), cytokeratin-18 (CK-18), serum autotaxin, fibroblast growth factor-19 (FGF-19), and bile salt export pump (BSEP), as well as the incidence of rejection, early allograft dysfunction (EAD), biliary complications, mortality, adverse events, and quality of life (QoL). Results: In the interim analysis of 83 patients, more than a 15% reduction in ALP between six and 12 months was observed in a higher proportion of patients in the OCA group (43%) than in the UDCA group (21%) (p=0.036). More than a 15% reduction in GGT between one and three months was observed in 80% of patients in the OCA group compared to 62% in the UDCA group (p=0.062). Plasma bile acids were lower in the OCA group at one month (170 vs. 226 µmol/L; p=0.012). Low-density lipoprotein (LDL)-cholesterol was higher in the OCA group at three (OCA 121 vs UDCA 107, p=0.027) and six months (OCA 130 vs UDCA 117, p=0.043). UDCA therapy resulted in a significantly greater improvement in overall QoL, with higher gains in both total mean and domain scores compared to OCA. No differences were detected in rejection, biliary complications, mortality, or other secondary endpoints. Conclusion: OCA led to greater biochemical improvement, while better QoL was achieved with UDCA in LDLT recipients, with a comparable safety profile.